Arlene Fedorchak, MD
Internal Medicine · Columbus, OHNPI 1891998340
Payments from drug & device makers
Across 296 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$658
- Lilly USA, LLC$445
- GSK$412
- Amgen$402
- AstraZeneca$370
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,959100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 74 | $1,069 |
| Novo Nordisk | 47 | $658 |
| Lilly USA, LLC | 20 | $445 |
| GSK | 22 | $412 |
| Amgen(2 entities) | 18 | $402 |
| AstraZeneca | 24 | $370 |
| Pfizer | 14 | $246 |
| Novartis | 12 | $193 |
| Abbott | 5 | $95 |
| Boehringer Ingelheim | 6 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Amarin Pharma, Inc. | 5 | $86 |
| Astellas Pharma US Inc | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $81 |
| Biohaven Pharmaceuticals, Inc. | 5 | $79 |
| Kowa Pharmaceuticals America, Inc. | 3 | $52 |
| Phathom Pharmaceuticals, Inc. | 3 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $40 |
| Bausch Health US, LLC | 3 | $40 |
| Bayer | 1 | $32 |
| Optinose US, Inc. | 1 | $27 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Dexcom, Inc. | 1 | $20 |
| Endo Pharmaceuticals Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Amphastar Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,971 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 183 | $192,727 |
| EliquisApixaban | 107 | $124,899 |
| MounjaroTirzepatide | 40 | $66,682 |
| OzempicSemaglutide | 41 | $56,889 |
| FarxigaDapagliflozin Propanediol | 25 | $31,966 |
| TrulicityDulaglutide | 22 | $29,732 |
| XareltoRivaroxaban | 19 | $24,696 |
| Repatha SureclickEvolocumab | 30 | $17,962 |
| MyrbetriqMirabegron | 29 | $17,931 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $17,328 |
| EntrestoSacubitril/Valsartan | 12 | $16,971 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $11,640 |
| VascepaIcosapent Ethyl | 14 | $10,737 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 27 | $8,483 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $88 | $192,727183 claims |
| PfizerEliquis, Abrysvo | $246 | $133,382134 claims |
| Lilly USA, LLCMounjaro, Trulicity | $445 | $96,41462 claims |
| Novo NordiskOzempic | $658 | $56,88941 claims |
| AstraZenecaFarxiga | $370 | $31,96625 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $412 | $27,01142 claims |
| Astellas Pharma US IncMyrbetriq | $82 | $17,93129 claims |
| NovartisEntresto | $193 | $16,97112 claims |
| AbbVieSynthroid | $1,069 | $3,99260 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $45 | $1,956258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Columbus
- Raghu KolluriColumbus$933K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.